Aventis Cuts to 3 in $100 Mil. Lantus Review

NEW YORK Aventis Pharmaceuticals cut to three shops on Friday in a global review for its Lantus diabetes drug, sources said. Billings are estimated at $100 million.

The cut came after presentations this week by five agencies: Interpublic Group’s McCann-Erickson, Omnicom Group’s TBWA Worldwide, Havas’ Euro RSCG, Grey Global Group’s Healthy Grey and WPP Group’s Young & Rubicam, said sources.

AW+

WORK SMARTER - LEARN, GROW AND BE INSPIRED.

Subscribe today!

To Read the Full Story Become an Adweek+ Subscriber

View Subscription Options

Already a member? Sign in